Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/01/22
Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational ProgressGlobeNewsWire • 02/28/22
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 02/16/22
Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual MeetingGlobeNewsWire • 12/13/21
Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCLGlobeNewsWire • 12/13/21
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/05/21
Fate Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Operational ProgressGlobeNewsWire • 11/04/21
Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual MeetingGlobeNewsWire • 11/04/21
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2021 Financial ResultsGlobeNewsWire • 10/25/21
Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual MeetingGlobeNewsWire • 10/01/21
Why Is Fate Therapeutics (FATE) Down 21% Since Last Earnings Report?Zacks Investment Research • 09/03/21